{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:28:01Z","timestamp":1770956881463,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2202-15-79","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T13:05:35Z","timestamp":1403701535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Naoto","family":"Kadoguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Fukano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akie","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"key":"3521_CR1","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom B: Parkinson's disease. Lancet. 2004, 363: 1783-1793.","journal-title":"Lancet"},{"key":"3521_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973, 20: 415-455.","journal-title":"J Neurol Sci"},{"key":"3521_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/0140-6736(91)92989-F","volume":"337","author":"Y Agid","year":"1991","unstructured":"Agid Y: Parkinson\u2019s disease: pathophysiology. Lancet. 1991, 337: 1321-1324.","journal-title":"Lancet"},{"key":"3521_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1212\/WNL.58.1.11","volume":"58","author":"JM Miyasaki","year":"2002","unstructured":"Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE: Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurol. 2002, 58: 11-17.","journal-title":"J Neurol"},{"key":"3521_CR5","first-page":"106","volume":"61","author":"L Jain","year":"2012","unstructured":"Jain L, Benko R, Safranek S: Clinical inquiry. Which drugs work best for early Parkinson's disease?. J Fam Pract. 2012, 61: 106-108.","journal-title":"J Fam Pract"},{"key":"3521_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00002826-200111000-00002","volume":"24","author":"O Rascol","year":"2001","unstructured":"Rascol O, Fabre N: Dyskinesia: \u029f-dopa-induced and tardive dyskinesia. Clin Neuropharmacol. 2001, 24: 313-323.","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl 1","key":"3521_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1353-8020(11)70040-2","volume":"18","author":"BN Mathur","year":"2012","unstructured":"Mathur BN, Lovinger DM: Serotonergic action on dorsal striatal function. Parkinsonism Relat Disord. 2012, 18 (Suppl 1): 129-131.","journal-title":"Parkinsonism Relat Disord"},{"key":"3521_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jocn.2011.09.008","volume":"19","author":"PA Cheshire","year":"2012","unstructured":"Cheshire PA, Williams DR: Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci. 2012, 19: 343-348.","journal-title":"J Clin Neurosci"},{"key":"3521_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","volume":"453","author":"EP Prinssen","year":"2002","unstructured":"Prinssen EP, Colpaert FC, Koek W: 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol. 2002, 453: 217-221.","journal-title":"Eur J Pharmacol"},{"key":"3521_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(25)38100-0","volume":"265","author":"BS Neal-Beliveau","year":"2003","unstructured":"Neal-Beliveau BS, Joyce JN, Lucki I: Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther. 2003, 265: 207-217.","journal-title":"J Pharmacol Exp Ther"},{"key":"3521_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1755-5949.2010.00211.x","volume":"17","author":"Y Ohno","year":"2011","unstructured":"Ohno Y: Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther. 2011, 17: 58-65.","journal-title":"CNS Neurosci Ther"},{"key":"3521_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003495-199957040-00010","volume":"57","author":"KJ Holm","year":"1999","unstructured":"Holm KJ, Markham A: Mirtazapine: a review of its use in major depression. Drugs. 1999, 57: 607-631.","journal-title":"Drugs"},{"issue":"Suppl 4","key":"3521_CR13","first-page":"19","volume":"10","author":"T De Boer","year":"1996","unstructured":"De Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1996, 10 (Suppl 4): 19-23.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 4","key":"3521_CR14","first-page":"19","volume":"57","author":"T De Boer","year":"1996","unstructured":"De Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996, 57 (Suppl 4): 19-25.","journal-title":"J Clin Psychiatry"},{"key":"3521_CR15","first-page":"519","volume":"56","author":"JD Bremner","year":"1995","unstructured":"Bremner JD: A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995, 56: 519-525.","journal-title":"J Clin Psychiatry"},{"key":"3521_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004850-199503000-00001","volume":"10","author":"M van Moffaert","year":"1995","unstructured":"van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J: Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995, 10: 3-9.","journal-title":"Int Clin Psychopharmacol"},{"key":"3521_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","volume":"51","author":"J Fawcett","year":"1998","unstructured":"Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998, 51: 267-285.","journal-title":"J Affect Disord"},{"key":"3521_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2710.2004.00585.x","volume":"30","author":"H Amini","year":"2005","unstructured":"Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M: Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther. 2005, 30: 133-138.","journal-title":"J Clin Pharm Ther"},{"key":"3521_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1600-0447.1996.tb10629.x","volume":"93","author":"OJ H\u00f8yberg","year":"1996","unstructured":"H\u00f8yberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C: A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996, 93: 184-190.","journal-title":"Acta Psychiatr Scand"},{"key":"3521_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.brainresbull.2004.02.007","volume":"63","author":"K Nakayama","year":"2004","unstructured":"Nakayama K, Sakurai T, Katsu H: Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull. 2004, 63: 237-241.","journal-title":"Brain Res Bull"},{"key":"3521_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"9","author":"PH Gordon","year":"2002","unstructured":"Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S: Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord. 2002, 9: 125-126.","journal-title":"Parkinsonism Relat Disord"},{"key":"3521_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","volume":"73","author":"SH Fox","year":"2013","unstructured":"Fox SH: Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013, 73: 1405-1415.","journal-title":"Drugs"},{"key":"3521_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/B978-0-12-415894-8.00026-9","volume-title":"Animal Models for The Study of Human Disease","author":"J Kasahara","year":"2013","unstructured":"Kasahara J, Choudhury ME, Yokoyama H, Kadoguchi N, Nomoto M: Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced animal models for Parkinson's disease. Animal Models for The Study of Human Disease. Edited by: Conn PM. 2013, London: Academic Press, 633-650."},{"key":"3521_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.55782\/ane-2011-1847","volume":"71","author":"H Yokoyama","year":"2011","unstructured":"Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp. 2011, 71: 269-280.","journal-title":"Acta Neurobiol Exp"},{"key":"3521_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11011-010-9191-0","volume":"25","author":"H Yokoyama","year":"2010","unstructured":"Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H, Kasahara J, Araki T: Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis. 2010, 25: 135-143.","journal-title":"Metab Brain Dis"},{"key":"3521_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1254\/jphs.09019FP","volume":"110","author":"H Yabe","year":"2009","unstructured":"Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M: Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci. 2009, 110: 64-68.","journal-title":"J Pharmacol Sci"},{"key":"3521_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0014-2999(93)90351-H","volume":"233","author":"J Grenhoff","year":"1993","unstructured":"Grenhoff J, Svensson TH: Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol. 1993, 233: 79-84.","journal-title":"Eur J Pharmacol"},{"key":"3521_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.153.4.466","volume":"153","author":"S Kapur","year":"1996","unstructured":"Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996, 153: 466-476.","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"3521_CR29","first-page":"3","volume":"26","author":"P Blier","year":"2001","unstructured":"Blier P: Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001, 26 (Suppl): 3-10.","journal-title":"J Psychiatry Neurosci"},{"key":"3521_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","volume":"279","author":"F Blandini","year":"2012","unstructured":"Blandini F, Armentero MT: Animal models of Parkinson's disease. FEBS J. 2012, 279: 1156-1166.","journal-title":"FEBS J"},{"key":"3521_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0304-3940(89)90550-8","volume":"101","author":"S Rose","year":"1989","unstructured":"Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD: Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett. 1989, 101: 305-310.","journal-title":"Neurosci Lett"},{"key":"3521_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev.pharmtox.43.050802.112309","volume":"43","author":"RR Gainetdinov","year":"2003","unstructured":"Gainetdinov RR, Caron MG: Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol. 2003, 43: 261-284.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3521_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1471-4159.2011.07335.x","volume":"118","author":"V Leviel","year":"2011","unstructured":"Leviel V: Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem. 2011, 118: 475-489.","journal-title":"J Neurochem"},{"key":"3521_CR34","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1046\/j.1471-4159.2001.00148.x","volume":"76","author":"L Dazzi","year":"2001","unstructured":"Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A, Jentsch JD, Biggio G: Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J Neurochem. 2001, 76: 1212-1220.","journal-title":"J Neurochem"},{"key":"3521_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001, 7: 249-264.","journal-title":"CNS Drug Rev"},{"key":"3521_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1755-5949.2010.00135.x","volume":"16","author":"G Di Giovanni","year":"2010","unstructured":"Di Giovanni G, Esposito E, Di Matteo V: Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther. 2010, 16: 179-194.","journal-title":"CNS Neurosci Ther"},{"key":"3521_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.tips.2007.10.009","volume":"28","author":"T Sharp","year":"2007","unstructured":"Sharp T, Boothman L, Raley J, Qu\u00e9r\u00e9e P: Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci. 2007, 28: 629-636.","journal-title":"Trends Pharmacol Sci"},{"key":"3521_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuropharm.2010.03.013","volume":"59","author":"MC Ferguson","year":"2010","unstructured":"Ferguson MC, Nayyar T, Deutch AY, Ansah TA: 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2010, 59: 31-36.","journal-title":"Neuropharmacology"},{"key":"3521_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00213-002-1121-3","volume":"163","author":"L Mignon","year":"2002","unstructured":"Mignon L, Wolf WA: Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology. 2002, 163: 85-94.","journal-title":"Psychopharmacology"},{"key":"3521_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1163\/1569391041501924","volume":"8","author":"T Ishibashi","year":"2004","unstructured":"Ishibashi T, Ohno Y: Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats. Biog Amines. 2004, 8: 329-338.","journal-title":"Biog Amines"},{"key":"3521_CR41","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","volume":"55","author":"KB Dupre","year":"2008","unstructured":"Dupre KB, Eskow KL, Barnum CJ, Bishop C: Striatal 5-HT1A receptor stimulation reduces D1 receptor-induce dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology. 2008, 55: 1321-1328.","journal-title":"Neuropharmacology"},{"key":"3521_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","volume":"34","author":"S Shimizu","year":"2010","unstructured":"Shimizu S, Tatara A, Imaki J, Ohno Y: Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuro-Psychopharmacol Biol Psychiat. 2010, 34: 877-881.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"3521_CR43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1755-5949.2010.00146.x","volume":"16","author":"M El Mansari","year":"2010","unstructured":"El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P: Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010, 16: e1-17.","journal-title":"CNS Neurosci Ther"},{"issue":"Suppl 4","key":"3521_CR44","first-page":"iv23","volume":"252","author":"N Ogawa","year":"2005","unstructured":"Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales F, Miyoshi K: \u029f-DOPA treatment from the viewpoint of neuroprotection: Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson\u2019s disease. J Neurol. 2005, 252 (Suppl 4): iv23-iv31.","journal-title":"J Neurol"},{"key":"3521_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Munenter MD: Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001, 16: 448-458.","journal-title":"Mov Disord"},{"key":"3521_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1254\/jphs.12003FP","volume":"119","author":"M Inden","year":"2012","unstructured":"Inden M, Abe M, Minamino H, Takata K, Yoshimoto K, Tooyama I, Kitamura Y: Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on \u029f-DOPA-induced rotational behavior in a hemiparkinsonian rat model. J Pharmacol Sci. 2012, 119: 10-19.","journal-title":"J Pharmacol Sci"},{"key":"3521_CR47","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/mds.23172","volume":"25","author":"TH Johnston","year":"2012","unstructured":"Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM: The \u03b12 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov Disord. 2012, 25: 2084-2093.","journal-title":"Mov Disord"},{"key":"3521_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1590\/S0004-282X2012000800011","volume":"70","author":"FH Costa","year":"2012","unstructured":"Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB: Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr. 2012, 70: 617-620.","journal-title":"Arq Neuropsiquiatr"},{"key":"3521_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrneurol.2012.111","volume":"8","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rascol O: Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol. 2012, 8: 365-366.","journal-title":"Nat Rev Neurol"},{"key":"3521_CR50","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1517\/14656566.1.7.1367","volume":"1","author":"PJ Goodnick","year":"2000","unstructured":"Goodnick PJ, Hernandez M: Treatment of depression in comorbid medical illness. Expert Opin Pharmacother. 2000, 1: 1367-1384.","journal-title":"Expert Opin Pharmacother"},{"key":"3521_CR51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10571-008-9271-4","volume":"28","author":"N Kadoguchi","year":"2008","unstructured":"Kadoguchi N, Umeda M, Kato H, Araki T: Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice. Cell Mol Neurobiol. 2008, 28: 971-979.","journal-title":"Cell Mol Neurobiol"},{"key":"3521_CR52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jneumeth.2006.07.006","volume":"159","author":"HN Allbutt","year":"2007","unstructured":"Allbutt HN, Henderson JM: Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods. 2007, 159: 195-202.","journal-title":"J Neurosci Methods"},{"key":"3521_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0928-0987(00)00170-6","volume":"12","author":"T Araki","year":"2001","unstructured":"Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y: Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci. 2001, 12: 231-238.","journal-title":"Eur J Pharm Sci"},{"key":"3521_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pbb.2004.03.006","volume":"78","author":"R Kurosaki","year":"2004","unstructured":"Kurosaki R, Muramatsu Y, Kato H, Araki T: Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav. 2004, 78: 143-153.","journal-title":"Pharmacol Biochem Behav"},{"key":"3521_CR55","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00702-007-0790-9","volume":"114","author":"S Takagi","year":"2007","unstructured":"Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T: Damage of oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm. 2007, 114: 1553-1557.","journal-title":"J Neural Transm"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-15-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:14:42Z","timestamp":1746278082000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-15-79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3521"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-15-79","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]},"assertion":[{"value":"14 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"79"}}